Leadership

The Neuropathix leadership team has more than 40 years of business, marketing and drug development experience with Fortune 500, Pharma and leading Biotechnology firms. Our scientific team, Board of Directors and Scientific Advisory Board are comprised of dedicated business professionals, clinicians and bio-chemists, all have a strong background in phyto-medical, biological and pharmaceutical sciences with a long track record of successful drug development and identifying phyto-medicine and therapeutics that are complex in nature and structure. Overall, the Neuropathix scientific team has over 75+ years of research and pharmaceutical experience and have been published in over 300 notable journal publications and jointly hold over 65 patents.

Executive Team

Dean-Petkanas

Dean Petkanas

Chairman & CEO
William-Kinney

William A. Kinney, PhD

Chief Scientific Officer
Thoma-Kikis

Thoma Kikis

Founder / Chief Communications Officer, Board Director
Mark-Corrao

Mark Corrao

Chief Financial Officer
Mark-McDonnell

Mark McDonnell, PhD

Chief Chemist
Doug-Brenneman

Douglas Brenneman, PhD

Chief Pharmacologist

Board of Directors

Dean-Petkanas

Dean Petkanas

Chairman & CEO
Thoma-Kikis

Thoma Kikis

Founder / Chief Communications Officer, Board Director
Robert-Malasek

Robert Malasek

Director
Blake-Schroeder

Blake Schroeder

Board Director
Timothy-Scott

Timothy Scott, PhD

Board Director

Scientific Advisory Board

Tage Honoré, Phd, DSc

Chairman of Scientific Advisory Board

Daniele Piomelli, PhD, MD

Scientific Advisory Board

Charles L. Loprinzi, MD

Scientific Advisory Board

Michael Ropacki, PhD

Scientific Advisory Board

Daniel Richman, MD

Scientific Advisory Board
Ryan-Turner

Ryan Turner, MD

Scientific Advisory Board
Jason-Clement

Jason Clement, PhD

Scientific Advisory Board

Terrence O. Tormey

Company Advisory Board
Nick-Lowery

Nick Lowery

NFL Liaison – Advisory Board